MustGrow Biologics (CSE: MGRO) this morning reported on results for the use of its mustard-based biopesticide within tobacco field trials. The study was focused on comparing the efficacy of its product with that of the synthetic chemical chloropicrin, a leading soil fumigation synthetic chemical.
Field trial results, which were conducted by a third part research organization, found that MustGrow’s biopesticide has comparable efficacy and yield results versus the synthetic chemical. The study specifically focused on plant growth, phytotocixitity, nematodes, and soil fungi, with the overall results being comparable. Further evaluation is being conducted once the tobacco leaves have been cured.
Field trial data collected by the third party will be used to potentially achieved product registration for the use of MustGrow’s biopesticide against diseases and insect pests in tobacco cultivation. The $28 billion industry is currently rife with opportunity for natural biopesticides as synthetic chemicals continue to be banned or deregistered, leaving farmers with few crop protection options.
The product is to continue to be evaluated in its effectiveness over the 2021 growing season to assess leaf yield and chemistry data once the tobacco leaves have been cured.
MustGrow Biologics last traded at $2.00 on the CSE.
FULL DISCLOSURE: MustGrow Biologics Corp is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover MustGrow Biologics Corp on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.